Cisplatin-paclitaxel weekly schedule in advanced solid tumors: A phase I study

Annals of Oncology

Volumn 8, Issue 3, 1997, Pages 291-293

  Frasci, G ^a   Comella, P ^a   Parziale, A ^a   Casaretti, R ^a   Daponte, A ^a   Gravina, A ^a   De Rosa, L ^a   Gallipoli, A ^a   Comella, G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

chemotherapy; cisplatin; paclitaxel; weekly schedule

Indexed keywords

CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; INFUSIONS, INTRAVENOUS; NEOPLASMS; PACLITAXEL; RETREATMENT;

EID: 0030948265     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008248627396     Document Type: Article

References (8)

1. Belli L, Le Chevalier T, Gottfried M et al. Phase I II trial of paclitaxel in previously untreated advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 1995; 14: 350 (Abstr 1058).
2. Akerley W, Choy H, Rege V et al. A phase I trial of weekly paclitaxel administered as a 3-hour infusion for metastatic non-small-cell lung cancer. Proc Am Soc Clin Oncol 1995; 14: 378 (Abstr 1170).
3. Glantz MJ, Choy H, Kearns CM et al. Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. J Clin Oncol 1996; 14: 600-9.
4. World Health Organization. Handbook for Reporting Results of Cancer Treatment, WHO Offset Publication no. 48, Geneva: WHO 1979.
5. Klastersky J, Sculier JP. Dose-finding study of paclitaxel plus cisplatin in patients with non-small cell lung cancer. Semin Oncol 1994; 21 (Suppl 8): 39-43.
6. Longnecker SM, Donehower RC, Cates AE et al. High-performance liquid chromatografic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 1987; 71: 53-9.
7. Gianni L, Kearns CM, Giani A et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13: 180-90.
8. Liebman JE, Cook JA, Lipschultz C et al. Cytotoxic studies of paclitaxel (taxol) in human tumor cell lines. Br J Cancer 1993; 68: 1104-9.